Dr. Lal Pathlabs Limited · NSE:LALPATHLAB
Dr. Lal Pathlabs — Q2 FY27 Earnings Presentation
31 slides from Dr. Lal Pathlabs's earnings presentation, Nov 4, 2026
Slide 1: Exchange filing cover letter
November 04, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza, Corporate Relationship Department Plot No. C/1, G Block, Phiroze Jeejeebhoy Towers Bandra Kurla Complex, Bandra (E) Dalal Street Mumbai – 400 051 Mumbai – 400 001 Symbol: LALPATHLAB Scrip Code: 539524 Sub: Earning
Slide 2: Results Presentation Q2 & H1 FY27
Results Presentation Q2 & H1 FY27
Slide 3: Disclaimer
Disclaimer By attending the meeting / telephonic call where this presentation is made, or by reading the presentation materials, you agree to be bound by the following limitations: The information in this presentation has been prepared by Dr Lal PathLabs Limited (the “Company”) for use in presentati
Slide 4: Table of Contents
Table of Contents DLPL - At a Glance 4 Q2 FY27 Performance Overview 5 H1 FY27 Performance Overview 6 Financials 7 Key Performance Highlights 8 Management Commentary 10 Shareholding 15 Corporate Overview 17 Contact Us 29 DISCLAIMER: This presentation may contain ‘forward-looking’ statements at places
Slide 5: Dr. Lal PathLabs – At a Glance
Dr. Lal PathLabs – At a Glance 7,700+ 75+ years of India’s 141 Mn 53 NABL & experience Leading & patients 2 CAP in the field Trusted serviced in accredited of Diagnostics last 5 years Labs Patient Service Centers(PSC’s) diagnostics Company 4,800+ Pathology, Radiology tests & Panels; Comprehensive Te
Slide 6: Q2 FY27 Performance Overview
Q2 FY27 Performance Overview Q2 FY27 Q2 FY26 Gr % Revenue (Rs. Cr.) 874 731 19.6% EBITDA (Rs. Cr.) 280 224 25.1% PAT (Rs. Cr.) 194 152 27.5% Patients (Mn) 9.0 8.2 9.0% Samples (Mn) 28.8 25.4 13.6% SwasthFitTM Contribution 26% 26% - 5
Slide 7: H1 FY27 Performance Overview
H1 FY27 Performance Overview H1 FY27 H1 FY26 Gr % Revenue (Rs. Cr.) 1,672 1,400 19.4% EBITDA (Rs. Cr.) 528 416 26.7% PAT (Rs. Cr.) 364 286 27.3% Patients (Mn) 17.2 15.8 8.6% Samples (Mn) 54.7 48.8 12.2% SwasthFitTM Contribution 27% 27% - 6
Slide 8: Financials
Financials Particulars (Rs. Cr.) Q2 FY27 Q2 FY26 Gr % H1 FY27 H1 FY26 Gr % Revenue 874 731 19.6% 1,672 1,400 19.4% Material consumed 162 142 314 271 Employee benefit Expenses 139 124 271 248 Fees to collection centres 129 109 245 204 Other Expenses 164 132 314 261 EBITDA 280 224 25.1% 528 416 26.7%
Slide 9: Key Performance Highlights – Q2 FY27
Key Performance Highlights – Q2 FY27 Continued Performance Momentum ➢ Delivered robust top-line growth (19.6% Y-o-Y), marking strongest Q2 revenue performance in recent years ➢ Operational Highlights: Core growth anchored by strong expansion across sample (+13.6% Y-o-Y) and patient (+9.0% Y-o-Y) vol
Slide 10: Operating highlights
Operating highlights No. of Clinical Laboratories No. of PSCs No. of PUPs +35 +2,625 +2,997 298 312 7,727 13,935 277 280 6,607 11,619 12,365 5,762 10,938 5,102 FY23 FY24 FY25 FY26 FY23 FY24 FY25 FY26 FY23 FY24 FY25 FY26 No. of Patients (Mn) No. of Samples (Mn) +3.4 +22.2 85.6 94.5 28.8 30.3 78.2 26.
Slide 11: Management Commentary
Management Commentary (Hony.) Brig. Dr. Arvind Lal, Mr. Shankha Banerjee, Mr. Ved Goel, Padma Shri Chief Executive Officer Group CFO & Executive Chairman CEO – International Business Commenting on the performance, (Hony) Brig Dr Arvind Commenting on the performance, Mr. Shankha Commenting on the per
Slide 12: Robust financial performance
Robust financial performance (INR Cr.) (INR Cr.) (INR Cr.) Revenue Cash and Cash Equivalents EBITDA, PAT and ROCE 2,763 1,746 2,461 1,526 EBITDA PAT 2,227 2,017 1,229 1,672 783# 696 877 609 490 492 532# 601 362 241 528 364 FY23 FY24 FY25 FY26 H1 FY27 FY23 FY24 FY25 FY26 H1 FY27 FY23 FY24 FY25 FY26 H
Slide 13: Expanding Revenue Footprint Across Emerging Markets
Expanding Revenue Footprint Across Emerging Markets Revenue Tier 3+ CAGR 16.7% Geography wise Revenue Others, 2% 39% 37% South India, 6% 34% 35% 2,763 West India, 14% Delhi & NCR, 31% 2,461 2,227 2,017 Revenue by 1,090 Geography 789 917 FY26 685 East India, 15% FY23 FY24 FY25 FY26 Revenue Tier 3+ (I
Slide 14: Medillumina: First International Medical Conference by DLPL
Medllumina: First International Medical Conference by DLPL Conference Platform for Advancing Collaboration for Precision Clinicians, Global Podcast Series Diagnostics Thought Leaders & Pathologists Case Study Integrating Clinician AI and Engagement & Next-Gen Advocacy Digital Engagement Technology N
Slide 15: Research & Academic collaborations
Research & Academic collaborations Academia Collaborations In House Sustainability Partnerships • Fundamental Research • Novel Solutions • Educational Initiatives • Improve Core Processes • DOCTORAL & Multi • Clinical Trials • 49 ethics-approved • Contribute to ESG Omics Projects projects Initiative
Slide 16: Shareholding as of 30th September 2026
Shareholding as of 30th September 2026 18.94% FPI’s & NRI’s 52.93% Promoter and Promoter Group 9.16% Others 18.97% Mutual Fund* Promoter and Promoter Group Mutual Funds* Others FPI's & NRI's 15 *Mutual Funds includes Alternate Investment Funds as well
Slide 17: Key Awards & Recognition
Key Awards & Recognition Outstanding Contribution Rotary India National CSR Award in Healthcare from Rotary India National CSR Best CFO Healthcare India 2030 Leadership The CFO of the year 2026 Awards-National Leve 2026 Foundation for Quality Awards-North Regional 2026 Conclave 2026 (India) in 2025
Slide 18: Corporate Overview
Corporate Overview NATIONAL KOLKATA BENGALURU MUMBAI REFERENCE LAB REFERENCE LAB REFERENCE LAB REFERENCE LAB 17
Slide 19: Indian Healthcare Services is a large and growing opportunity
Indian Healthcare Services is a large and growing opportunity ~1.51 bn 5% USD 1.5 trillion ~39% ~INR 1 trillion INR 42 billion India’s expected India’s projected spend Expected India’s Out of pocket expenses Allocated to the Allocated for Pradhan population on healthcare (as % of healthcare industry
Slide 20: Drivers of India diagnostic services market
Drivers of India diagnostic services market Lifestyle Diseases Longer Lifespans Preventive Checkups Growth Higher GDP per Drivers capita Evidence based Govt. Spend on treatment Primary Healthcare 19
Slide 21: Diagnostic Services industry continues to remain highly fragmented
Diagnostic Services industry continues to remain highly fragmented Highly Fragmented Industry Standalone Regional Centres Chains 42-46% 55% 16-20% Diagnostic Chains Multi- 36-40% Regional Hospital Based Labs 45% 20 Source: Industry Data
Slide 22: Our Evolution
Our Evolution 1949-2005 2005-2015 2015-2020 2020-2025 2025 onwards Foundation Building capabilities Higher contribution Pan India Player – Precision for scale up in from Rest of India, Acquired Suburban, Diagnostics, • 1949: Founded by Dr. geographies outside Commissioned state Building South Levera
Slide 23: Most trusted healthcare brand in Diagnostic Services
Most trusted healthcare brand in Diagnostic Services 30.3M+ 13,900+ 4,800+ 53 2 Patients Serviced Pick-up Points Pathology & Radiology NABL Accredited CAP Accredited in FY26 tests; Comprehensive Labs Labs Test menu Coverage in 24x7 access Centrally Accreditations metros, Wide reach including adminis
Slide 24: Scaling Rural Healthcare
Scaling Rural Healthcare GraminFit is creating a scalable rural preventive healthcare program, unlocking a large underserved diagnostics market. Expanded Reach -7 States Attract Educate Convert UP, Bihar, MP, Raj, Jharkhand Orissa, West Bengal Patients served more than 100K in Q1 FY27 Village Mandi
Slide 25: DLPL Strategy for future growth
DLPL Strategy for future growth Scientific AI Technology New Revenue Leadership Models Patient Merger & Experience Acquisitions Operational International Excellence Business People 24
Slide 26: Unleashing Digital Transformation
Unleashing Digital Transformation Driving efficiency & elevating customer experience Operations Consumers Medical • GenAl & curated healthcare • Unified Communication Engine • Smart Culture Reporting: models managing interactions • WhatsApp as forefront Advancing Quality through • 90% queries handle
Slide 27: Cyber Security Capability
Cyber Security Capability • SASE - Secure Access Service Edge, Extended • Digital Risk Management Platform • EDR - Endpoint Detection & Response Threat Detection • Proactive detection and mitigation of Intelligence & Response • Cloud Native SIEM/SOAR for AI-driven security vulnerabilities of publicl
Slide 28: Highest Quality Standards in the Industry
Highest Quality Standards in the Industry Best in the Industry CAP Proficiency Testing Score at 98.1% for National Reference Lab Consistently high EQAS Performance Testing Score at 98.2% for Satellite Labs CAP accreditation 2 labs, NABL accreditation 53 labs 100+ Quality Real time NABL Tech Assure i
Slide 29: Key ESG Initiatives
Key ESG Initiatives Use of biodegradable Installed R32 refrigerant bags for sample operated Inverter AC for collection Conserving ozone layer Saved 2515 Metric ton All labs are equipped of CO2 emissions by with Effluent Treatment using Solar power Plant for wastewater treatment Use of Electric 56,71
Slide 30: Contact Us
Contact Us About Dr. Lal PathLabs Limited (DLPL) Dr. Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests
Slide 31: Thank you
3D Lat Pathlabe